The Central Drugs Standard Control Organisation on 1st July 2020 has suggested the use of Convalescent plasma in moderate COVID-19 patients who are not improving despite the use of steroids. The therapy involves taking antibodies from the blood of a person who has recovered from COVID-19 and transfusing those into a coronavirus-infected patient to help kickstart the immune system to fight the infection.
Special prerequisites while considering convalescent plasma include, ABO compatibility and cross-matching of the donor plasma. Recipient should be closely monitored for several hours post-transfusion for any transfusion related adverse events and the use should be avoided in patients with IgA deficiency or immunoglobulin allergy.
Click here to read the notification.
